tiprankstipranks
DBV Technologies Reports Positive Phase 3 Study Results
Company Announcements

DBV Technologies Reports Positive Phase 3 Study Results

Story Highlights
  • DBV Technologies focuses on food allergies, primarily developing the VIASKIN Peanut patch.
  • The EPITOPE study shows the VIASKIN Peanut patch’s improved efficacy and safety over 36 months.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Stay Ahead of the Market:

DBV Technologies SA – American ( (DBVT) ) has shared an update.

DBV Technologies announced positive results from the EPITOPE Phase 3 Open-Label Extension Study, demonstrating continued improvement in the efficacy and safety of the VIASKIN Peanut patch over 36 months. The study showed significant increases in the number of participants reaching higher eliciting doses and completing oral food challenges without adverse events. This data supports the company’s proposed labeling approach to the FDA and highlights the potential of VIASKIN Peanut as an effective treatment for peanut allergies in young children.

More about DBV Technologies SA – American

DBV Technologies SA is a clinical-stage biopharmaceutical company that focuses on developing treatments for food allergies. Its primary product is the VIASKIN Peanut patch, which is designed to treat peanut allergies in toddlers aged 1 to 3 years.

YTD Price Performance: 6.77%

Average Trading Volume: 256,437

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $68.9M

See more data about DBVT stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App